Confirmation by several European agencies and the U.S. FDA of the relevance of the continuous abstinence validation criteria which showed statistical significance (p=0.02) in the Phase 2 CESTO II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback